Phase III STAR trial results published in Annals of Neurology
Avanir Pharmaceuticals, Inc announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. (Source: Multiple Sclerosis Trust)div id=medwormpbiMedWorm Message:/i/b Please have a look at this new site driven by MedWorm: a href=http://www.thebreastcancerdaily.com/ target=_blankThe Breast Cancer Daily/a/p/div

Site-specific regulation of ion transport by prolactin in rat colon epithelium
The effect of prolactin (PRL) on ion transport across the rat colon epithelium was investigated using Ussing chamber technique. PRL (1 mu;g/ml) induced a sustained decrease in short-circuit current (Isc) in the distal colon with an EC50 value of 100 ng/ml and increased Isc in the proximal colon with an EC50 value of 49 ng/ml. In the distal colon, the PRL-induced decrease in Isc was not affected by Na+ channel blocker amiloride or Clndash; channel blockers, NPPB, DPC, or DIDS, added mucosally. However, the response was inhibited by mucosal application of K+ channel blockers glibenclamide, quinidine, and chromanol 293B, whereas other K+ channel blockers, Ba2+, tetraethylammonium, clotrimazole, and apamin, failed to have effects. The PRL-induced decrease in Isc was also inhibited by Na+-K+-...